Susannah Fleming, Lazaro Mwandigha, Thomas R Fanshawe
{"title":"Practical and analytical considerations when performing interim analyses in diagnostic test accuracy studies.","authors":"Susannah Fleming, Lazaro Mwandigha, Thomas R Fanshawe","doi":"10.1186/s41512-024-00174-4","DOIUrl":"10.1186/s41512-024-00174-4","url":null,"abstract":"<p><p>Interim analysis is a common methodology in randomised clinical trials but has received less attention in studies of diagnostic test accuracy. In such studies, early termination for futility may be beneficial if early evidence indicates that a diagnostic test is unlikely to achieve a clinically useful level of diagnostic performance, as measured by the sensitivity and specificity. In this paper, we describe relevant practical and analytical considerations when planning and performing interim analysis in diagnostic accuracy studies, focusing on stopping rules for futility. We present an adaptation of the exact group sequential method for diagnostic testing, with R code provided for implementing this method in practice. The method is illustrated using two simulated data sets and data from a published diagnostic accuracy study for point-of-care testing for SARS-CoV-2. The considerations described in this paper can be used to guide decisions as to when an interim analysis in a diagnostic accuracy study is suitable and highlight areas for further methodological development.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"12"},"PeriodicalIF":0.0,"publicationDate":"2024-08-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11334588/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142006023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Victoria Watson, Catrin Tudur Smith, Laura J Bonnett
{"title":"Systematic review of methods used in prediction models with recurrent event data.","authors":"Victoria Watson, Catrin Tudur Smith, Laura J Bonnett","doi":"10.1186/s41512-024-00173-5","DOIUrl":"10.1186/s41512-024-00173-5","url":null,"abstract":"<p><strong>Background: </strong>Patients who suffer from chronic conditions or diseases are susceptible to experiencing repeated events of the same type (e.g. seizures), termed 'recurrent events'. Prediction models can be used to predict the risk of recurrence so that intervention or management can be tailored accordingly, but statistical methodology can vary. The objective of this systematic review was to identify and describe statistical approaches that have been applied for the development and validation of multivariable prediction models with recurrent event data. A secondary objective was to informally assess the characteristics and quality of analysis approaches used in the development and validation of prediction models of recurrent event data.</p><p><strong>Methods: </strong>Searches were run in MEDLINE using a search strategy in 2019 which included index terms and phrases related to recurrent events and prediction models. For studies to be included in the review they must have developed or validated a multivariable clinical prediction model for recurrent event outcome data, specifically modelling the recurrent events and the timing between them. The statistical analysis methods used to analyse the recurrent event data in the clinical prediction model were extracted to answer the primary aim of the systematic review. In addition, items such as the event rate as well as any discrimination and calibration statistics that were used to assess the model performance were extracted for the secondary aim of the review.</p><p><strong>Results: </strong>A total of 855 publications were identified using the developed search strategy and 301 of these are included in our systematic review. The Andersen-Gill method was identified as the most commonly applied method in the analysis of recurrent events, which was used in 152 (50.5%) studies. This was closely followed by frailty models which were used in 116 (38.5%) included studies. Of the 301 included studies, only 75 (24.9%) internally validated their model(s) and three (1.0%) validated their model(s) in an external dataset.</p><p><strong>Conclusions: </strong>This review identified a variety of methods which are used in practice when developing or validating prediction models for recurrent events. The variability of the approaches identified is cause for concern as it indicates possible immaturity in the field and highlights the need for more methodological research to bring greater consistency in approach of recurrent event analysis. Further work is required to ensure publications report all required information and use robust statistical methods for model development and validation.</p><p><strong>Prospero registration: </strong>CRD42019116031.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"13"},"PeriodicalIF":0.0,"publicationDate":"2024-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11302841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141894934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Flavia L Lombardo, Patrizia Lorenzini, Flavia Mayer, Marco Massari, Paola Piscopo, Ilaria Bacigalupo, Antonio Ancidoni, Francesco Sciancalepore, Nicoletta Locuratolo, Giulia Remoli, Simone Salemme, Stefano Cappa, Daniela Perani, Patrizia Spadin, Fabrizio Tagliavini, Alberto Redolfi, Maria Cotelli, Camillo Marra, Naike Caraglia, Fabrizio Vecchio, Francesca Miraglia, Paolo Maria Rossini, Nicola Vanacore
{"title":"Development of a prediction model of conversion to Alzheimer's disease in people with mild cognitive impairment: the statistical analysis plan of the INTERCEPTOR project.","authors":"Flavia L Lombardo, Patrizia Lorenzini, Flavia Mayer, Marco Massari, Paola Piscopo, Ilaria Bacigalupo, Antonio Ancidoni, Francesco Sciancalepore, Nicoletta Locuratolo, Giulia Remoli, Simone Salemme, Stefano Cappa, Daniela Perani, Patrizia Spadin, Fabrizio Tagliavini, Alberto Redolfi, Maria Cotelli, Camillo Marra, Naike Caraglia, Fabrizio Vecchio, Francesca Miraglia, Paolo Maria Rossini, Nicola Vanacore","doi":"10.1186/s41512-024-00172-6","DOIUrl":"10.1186/s41512-024-00172-6","url":null,"abstract":"<p><strong>Background: </strong>In recent years, significant efforts have been directed towards the research and development of disease-modifying therapies for dementia. These drugs focus on prodromal (mild cognitive impairment, MCI) and/or early stages of Alzheimer's disease (AD). Literature evidence indicates that a considerable proportion of individuals with MCI do not progress to dementia. Identifying individuals at higher risk of developing dementia is essential for appropriate management, including the prescription of new disease-modifying therapies expected to become available in clinical practice in the near future.</p><p><strong>Methods: </strong>The ongoing INTERCEPTOR study is a multicenter, longitudinal, interventional, non-therapeutic cohort study designed to enroll 500 individuals with MCI aged 50-85 years. The primary aim is to identify a biomarker or a set of biomarkers able to accurately predict the conversion from MCI to AD dementia within 3 years of follow-up. The biomarkers investigated in this study are neuropsychological tests (mini-mental state examination (MMSE) and delayed free recall), brain glucose metabolism ([<sup>18</sup>F]FDG-PET), MRI volumetry of the hippocampus, EEG brain connectivity, cerebrospinal fluid (CSF) markers (p-tau, t-tau, Aβ1-42, Aβ1-42/1-40 ratio, Aβ1-42/p-Tau ratio) and APOE genotype. The baseline visit includes a full cognitive and neuropsychological evaluation, as well as the collection of clinical and socio-demographic information. Prognostic models will be developed using Cox regression, incorporating individual characteristics and biomarkers through stepwise selection. Model performance will be evaluated in terms of discrimination and calibration and subjected to internal validation using the bootstrapping procedure. The final model will be visually represented as a nomogram.</p><p><strong>Discussion: </strong>This paper contains a detailed description of the statistical analysis plan to ensure the reproducibility and transparency of the analysis. The prognostic model developed in this study aims to identify the population with MCI at higher risk of developing AD dementia, potentially eligible for drug prescriptions. The nomogram could provide a valuable tool for clinicians for risk stratification and early treatment decisions.</p><p><strong>Trial registration: </strong>ClinicalTrials.gov NCT03834402. Registered on February 8, 2019.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"11"},"PeriodicalIF":0.0,"publicationDate":"2024-07-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11271065/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141763069","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Natasha Samsunder, Aida Sivro, Razia Hassan-Moosa, Lara Lewis, Zahra Kara, Cheryl Baxter, Quarraisha Abdool Karim, Salim Abdool Karim, Ayesha B M Kharsany, Kogieleum Naidoo, Sinaye Ngcapu
{"title":"Evaluating diagnostic accuracy of an RT-PCR test for the detection of SARS-CoV-2 in saliva.","authors":"Natasha Samsunder, Aida Sivro, Razia Hassan-Moosa, Lara Lewis, Zahra Kara, Cheryl Baxter, Quarraisha Abdool Karim, Salim Abdool Karim, Ayesha B M Kharsany, Kogieleum Naidoo, Sinaye Ngcapu","doi":"10.1186/s41512-024-00176-2","DOIUrl":"10.1186/s41512-024-00176-2","url":null,"abstract":"<p><strong>Background and objective: </strong>Saliva has been proposed as a potential more convenient, cost-effective, and easier sample for diagnosing SARS-CoV-2 infections, but there is limited knowledge of the impact of saliva volumes and stages of infection on its sensitivity and specificity.</p><p><strong>Methods: </strong>In this study, we assessed the performance of SARS-CoV-2 testing in 171 saliva samples from 52 mostly mildly symptomatic patients (aged 18 to 70 years) with a positive reference standard result at screening. The samples were collected at different volumes (50, 100, 300, and 500 µl of saliva) and at different stages of the disease (at enrollment, day 7, 14, and 28 post SARS-CoV-2 diagnosis). Imperfect nasopharyngeal (NP) swab nucleic acid amplification testing was used as a reference. We used a logistic regression with generalized estimating equations to estimate sensitivity, specificity, PPV, and NPV, accounting for the correlation between repeated observations.</p><p><strong>Results: </strong>The sensitivity and specificity values were consistent across saliva volumes. The sensitivity of saliva samples ranged from 70.2% (95% CI, 49.3-85.0%) for 100 μl to 81.0% (95% CI, 51.9-94.4%) for 300 μl of saliva collected. The specificity values ranged between 75.8% (95% CI, 55.0-88.9%) for 50 μl and 78.8% (95% CI, 63.2-88.9%) for 100 μl saliva compared to NP swab samples. The overall percentage of positive results in NP swabs and saliva specimens remained comparable throughout the study visits. We observed no significant difference in cycle number values between saliva and NP swab specimens, irrespective of saliva volume tested.</p><p><strong>Conclusions: </strong>The saliva collection offers a promising approach for population-based testing.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"9"},"PeriodicalIF":0.0,"publicationDate":"2024-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11267770/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jung Yin Tsang, Matthew Sperrin, Thomas Blakeman, Rupert A Payne, Darren M Ashcroft
{"title":"Protocol for the development and validation of a Polypharmacy Assessment Score.","authors":"Jung Yin Tsang, Matthew Sperrin, Thomas Blakeman, Rupert A Payne, Darren M Ashcroft","doi":"10.1186/s41512-024-00171-7","DOIUrl":"10.1186/s41512-024-00171-7","url":null,"abstract":"<p><strong>Background: </strong>An increasing number of people are using multiple medications each day, named polypharmacy. This is driven by an ageing population, increasing multimorbidity, and single disease-focussed guidelines. Medications carry obvious benefits, yet polypharmacy is also linked to adverse consequences including adverse drug events, drug-drug and drug-disease interactions, poor patient experience and wasted resources. Problematic polypharmacy is 'the prescribing of multiple medicines inappropriately, or where the intended benefits are not realised'. Identifying people with problematic polypharmacy is complex, as multiple medicines can be suitable for people with several chronic conditions requiring more treatment. Hence, polypharmacy is often potentially problematic, rather than always inappropriate, dependent on clinical context and individual benefit vs risk. There is a need to improve how we identify and evaluate these patients by extending beyond simple counts of medicines to include individual factors and long-term conditions.</p><p><strong>Aim: </strong>To produce a Polypharmacy Assessment Score to identify a population with unusual levels of prescribing who may be at risk of potentially problematic polypharmacy.</p><p><strong>Methods: </strong>Analyses will be performed in three parts: 1. A prediction model will be constructed using observed medications count as the dependent variable, with age, gender and long-term conditions as independent variables. A 'Polypharmacy Assessment Score' will then be constructed through calculating the differences between the observed and expected count of prescribed medications, thereby highlighting people that have unexpected levels of prescribing. Parts 2 and 3 will examine different aspects of validity of the Polypharmacy Assessment Score: 2. To assess 'construct validity', cross-sectional analyses will evaluate high-risk prescribing within populations defined by a range of Polypharmacy Assessment Scores, using both explicit (STOPP/START criteria) and implicit (Medication Appropriateness Index) measures of inappropriate prescribing. 3. To assess 'predictive validity', a retrospective cohort study will explore differences in clinical outcomes (adverse drug reactions, unplanned hospitalisation and all-cause mortality) between differing scores.</p><p><strong>Discussion: </strong>Developing a cross-cutting measure of polypharmacy may allow healthcare professionals to prioritise and risk stratify patients with polypharmacy using unusual levels of prescribing. This would be an improvement from current approaches of either using simple cutoffs or narrow prescribing criteria.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"10"},"PeriodicalIF":0.0,"publicationDate":"2024-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11251249/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141621901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Emmert Roberts, John Strang, Patrick Horgan, Brian Eastwood
{"title":"The development and internal validation of a multivariable model predicting 6-month mortality for people with opioid use disorder presenting to community drug services in England: a protocol","authors":"Emmert Roberts, John Strang, Patrick Horgan, Brian Eastwood","doi":"10.1186/s41512-024-00170-8","DOIUrl":"https://doi.org/10.1186/s41512-024-00170-8","url":null,"abstract":"","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"9 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140698514","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Amier Hassan, Brian Critelli, Ila Lahooti, Ali Lahooti, Nate Matzko, Jan Niklas Adams, Lukas Liss, Justin Quion, David Restrepo, Melica Nikahd, Stacey Culp, Lydia Noh, Kathleen Tong, Jun Sung Park, Venkata Akshintala, John A Windsor, Nikhil K Mull, Georgios I Papachristou, Leo Anthony Celi, Peter J Lee
{"title":"Critical appraisal of machine learning prognostic models for acute pancreatitis: protocol for a systematic review.","authors":"Amier Hassan, Brian Critelli, Ila Lahooti, Ali Lahooti, Nate Matzko, Jan Niklas Adams, Lukas Liss, Justin Quion, David Restrepo, Melica Nikahd, Stacey Culp, Lydia Noh, Kathleen Tong, Jun Sung Park, Venkata Akshintala, John A Windsor, Nikhil K Mull, Georgios I Papachristou, Leo Anthony Celi, Peter J Lee","doi":"10.1186/s41512-024-00169-1","DOIUrl":"10.1186/s41512-024-00169-1","url":null,"abstract":"<p><p>Acute pancreatitis (AP) is an acute inflammatory disorder that is common, costly, and is increasing in incidence worldwide with over 300,000 hospitalizations occurring yearly in the United States alone. As its course and outcomes vary widely, a critical knowledge gap in the field has been a lack of accurate prognostic tools to forecast AP patients' outcomes. Despite several published studies in the last three decades, the predictive performance of published prognostic models has been found to be suboptimal. Recently, non-regression machine learning models (ML) have garnered intense interest in medicine for their potential for better predictive performance. Each year, an increasing number of AP models are being published. However, their methodologic quality relating to transparent reporting and risk of bias in study design has never been systematically appraised. Therefore, through collaboration between a group of clinicians and data scientists with appropriate content expertise, we will perform a systematic review of papers published between January 2021 and December 2023 containing artificial intelligence prognostic models in AP. To systematically assess these studies, the authors will leverage the CHARMS checklist, PROBAST tool for risk of bias assessment, and the most current version of the TRIPOD-AI. (Research Registry ( http://www.reviewregistry1727 .).</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2024-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10986113/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140337854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Michael Bonares, Stacey Fisher, Kieran Quinn, Kirsten Wentlandt, Peter Tanuseputro
{"title":"Study protocol for the development and validation of a clinical prediction tool to estimate the risk of 1-year mortality among hospitalized patients with dementia.","authors":"Michael Bonares, Stacey Fisher, Kieran Quinn, Kirsten Wentlandt, Peter Tanuseputro","doi":"10.1186/s41512-024-00168-2","DOIUrl":"10.1186/s41512-024-00168-2","url":null,"abstract":"<p><strong>Background: </strong>Patients with dementia and their caregivers could benefit from advance care planning though may not be having these discussions in a timely manner or at all. A prognostic tool could serve as a prompt to healthcare providers to initiate advance care planning among patients and their caregivers, which could increase the receipt of care that is concordant with their goals. Existing prognostic tools have limitations. We seek to develop and validate a clinical prediction tool to estimate the risk of 1-year mortality among hospitalized patients with dementia.</p><p><strong>Methods: </strong>The derivation cohort will include approximately 235,000 patients with dementia, who were admitted to hospital in Ontario from April 1st, 2009, to December 31st, 2017. Predictor variables will be fully prespecified based on a literature review of etiological studies and existing prognostic tools, and on subject-matter expertise; they will be categorized as follows: sociodemographic factors, comorbidities, previous interventions, functional status, nutritional status, admission information, previous health care utilization. Data-driven selection of predictors will be avoided. Continuous predictors will be modelled as restricted cubic splines. The outcome variable will be mortality within 1 year of admission, which will be modelled as a binary variable, such that a logistic regression model will be estimated. Predictor and outcome variables will be derived from linked population-level healthcare administrative databases. The validation cohort will comprise about 63,000 dementia patients, who were admitted to hospital in Ontario from January 1st, 2018, to March 31st, 2019. Model performance, measured by predictive accuracy, discrimination, and calibration, will be assessed using internal (temporal) validation. Calibration will be evaluated in the total validation cohort and in subgroups of importance to clinicians and policymakers. The final model will be based on the full cohort.</p><p><strong>Discussion: </strong>We seek to develop and validate a clinical prediction tool to estimate the risk of 1-year mortality among hospitalized patients with dementia. The model would be integrated into the electronic medical records of hospitals to automatically output 1-year mortality risk upon hospitalization. The tool could serve as a trigger for advance care planning and inform access to specialist palliative care services with prognosis-based eligibility criteria. Before implementation, the tool will require external validation and study of its potential impact on clinical decision-making and patient outcomes.</p><p><strong>Trial registration: </strong>NCT05371782.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2024-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10949607/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140159637","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Blood levels of glial fibrillary acidic protein for predicting clinical progression to Alzheimer's disease in adults without dementia: a systematic review and meta-analysis protocol.","authors":"Takashi Nihashi, Keita Sakurai, Takashi Kato, Yasuyuki Kimura, Kengo Ito, Akinori Nakamura, Teruhiko Terasawa","doi":"10.1186/s41512-024-00167-3","DOIUrl":"10.1186/s41512-024-00167-3","url":null,"abstract":"<p><strong>Background: </strong>There is urgent clinical need to identify reliable prognostic biomarkers that predict the progression of dementia symptoms in individuals with early-phase Alzheimer's disease (AD) especially given the research on and predicted applications of amyloid-beta (Aβ)-directed immunotherapies to remove Aβ from the brain. Cross-sectional studies have reported higher levels of cerebrospinal fluid and blood glial fibrillary acidic protein (GFAP) in individuals with AD-associated dementia than in cognitively unimpaired individuals. Further, recent longitudinal studies have assessed the prognostic potential of baseline blood GFAP levels as a predictor of future cognitive decline in cognitively unimpaired individuals and in those with mild cognitive impairment (MCI) due to AD. In this systematic review and meta-analysis, we propose analyzing longitudinal studies on blood GFAP levels to predict future cognitive decline.</p><p><strong>Methods: </strong>This study will include prospective and retrospective cohort studies that assessed blood GFAP levels as a prognostic factor and any prediction models that incorporated blood GFAP levels in cognitively unimpaired individuals or those with MCI. The primary outcome will be conversion to MCI or AD in cognitively unimpaired individuals or conversion to AD in individuals with MCI. Articles from PubMed and Embase will be extracted up to December 31, 2023, without language restrictions. An independent dual screening of abstracts and potentially eligible full-text reports will be conducted. Data will be dual-extracted using the CHeck list for critical appraisal, data extraction for systematic Reviews of prediction Modeling Studies (CHARMS)-prognostic factor, and CHARMS checklists, and we will dual-rate the risk of bias and applicability using the Quality In Prognosis Studies and Prediction Study Risk-of-Bias Assessment tools. We will qualitatively synthesize the study data, participants, index biomarkers, predictive model characteristics, and clinical outcomes. If appropriate, random-effects meta-analyses will be performed to obtain summary estimates. Finally, we will assess the body of evidence using the Grading of Recommendation, Assessment, Development, and Evaluation Approach.</p><p><strong>Discussion: </strong>This systematic review and meta-analysis will comprehensively evaluate and synthesize existing evidence on blood GFAP levels for prognosticating presymptomatic individuals and those with MCI to help advance risk-stratified treatment strategies for early-phase AD.</p><p><strong>Trial registration: </strong>PROSPERO CRD42023481200.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913586/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140029676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Alpamys Issanov, Atul Aravindakshan, Lorri Puil, Martin C Tammemägi, Stephen Lam, Trevor J B Dummer
{"title":"Risk prediction models for lung cancer in people who have never smoked: a protocol of a systematic review.","authors":"Alpamys Issanov, Atul Aravindakshan, Lorri Puil, Martin C Tammemägi, Stephen Lam, Trevor J B Dummer","doi":"10.1186/s41512-024-00166-4","DOIUrl":"10.1186/s41512-024-00166-4","url":null,"abstract":"<p><strong>Background: </strong>Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related death worldwide. Although smoking is the primary cause of the cancer, lung cancer is also commonly diagnosed in people who have never smoked. Currently, the proportion of people who have never smoked diagnosed with lung cancer is increasing. Despite this alarming trend, this population is ineligible for lung screening. With the increasing proportion of people who have never smoked among lung cancer cases, there is a pressing need to develop prediction models to identify high-risk people who have never smoked and include them in lung cancer screening programs. Thus, our systematic review is intended to provide a comprehensive summary of the evidence on existing risk prediction models for lung cancer in people who have never smoked.</p><p><strong>Methods: </strong>Electronic searches will be conducted in MEDLINE (Ovid), Embase (Ovid), Web of Science Core Collection (Clarivate Analytics), Scopus, and Europe PMC and Open-Access Theses and Dissertations databases. Two reviewers will independently perform title and abstract screening, full-text review, and data extraction using the Covidence review platform. Data extraction will be performed based on the Checklist for Critical Appraisal and Data Extraction for Systematic Reviews of Prediction Modeling Studies (CHARMS). The risk of bias will be evaluated independently by two reviewers using the Prediction model Risk-of-Bias Assessment Tool (PROBAST) tool. If a sufficient number of studies are identified to have externally validated the same prediction model, we will combine model performance measures to evaluate the model's average predictive accuracy (e.g., calibration, discrimination) across diverse settings and populations and explore sources of heterogeneity.</p><p><strong>Discussion: </strong>The results of the review will identify risk prediction models for lung cancer in people who have never smoked. These will be useful for researchers planning to develop novel prediction models, and for clinical practitioners and policy makers seeking guidance for clinical decision-making and the formulation of future lung cancer screening strategies for people who have never smoked.</p><p><strong>Systematic review registration: </strong>This protocol has been registered in PROSPERO under the registration number CRD42023483824.</p>","PeriodicalId":72800,"journal":{"name":"Diagnostic and prognostic research","volume":"8 1","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2024-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10863273/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139725156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}